supplmental new drug application (sNDA)

The US Food and Drug Administration (FDA) has accepted and granted priority review of a supplemental new drug application (sNDA) for Lynparza to be used in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer. more


FDA approves sNDA for eltrombopag in patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy. more